KalVista Pharmaceuticals, Inc. (KALV)
| Market Cap | 461.63M |
| Revenue (ttm) | 3.82M |
| Net Income (ttm) | -51.54M |
| Shares Out | 24.43M |
| EPS (ttm) | -2.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 208,059 |
| Open | 18.61 |
| Previous Close | 18.88 |
| Day's Range | 18.32 - 19.00 |
| 52-Week Range | 12.01 - 45.00 |
| Beta | 1.97 |
| Analysts | Strong Buy |
| Price Target | 53.57 (+188.8%) |
| Est. Earnings Date | Dec 9, 2021 |
About KALV
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical tr...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KALV stock is "Strong Buy." The 12-month stock price forecast is 53.57, which is an increase of 188.79% from the latest price.
News
KalVista Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercia...
FDA Lifts Clinical Hold On KalVista's Hereditary Angioedema Trial
The FDA has lifted the clinical hold on KalVista Pharmaceuticals Inc's (NASDAQ: KALV) Phase 2 trial of KVD824 for oral prophylactic treatment of hereditary angioedema (HAE). Related Content: KalVista ...
KalVista Pharmaceuticals Announces the Lifting of FDA Clinical Hold for Phase 2 Trial of KVD824
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted five newly...
KalVista Pharmaceuticals Provides Progress Update on Phase 2 Clinical Trial of KVD824 for Oral Prophylactic Treatment...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals Presents Data Showing Single On-Demand Treatment with Orally Administered KVD900 Significant...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV #EAACI2021--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development,...
Analysts Estimate KalVista Pharmaceuticals, Inc. (KALV) to Report a Decline in Earnings: What to Look Out for
KalVista Pharmaceuticals, Inc. (KALV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KalVista Pharmaceuticals to Present Data at the European Academy of Allergy and Clinical Immunology (EAACI)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficienc...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
KalVista Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization...
KalVista Pharmaceuticals to Present Clinical Data of KVD900 for the Oral Treatment of Hereditary Angioedema at the 12...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
KalVista Pharmaceuticals Expands Senior Leadership Team with Appointment of Paul K. Audhya, MD, MBA as Chief Medical ...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
Why Crispr, KalVista And Syndax Are Moving Today
CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Ri...
KalVista Stock Falls After FDA Institutes Clinical Hold On Hereditary Angioedema Trial With KVD824
Two months after KalVista Pharmaceuticals Inc (NASDAQ: KALV) reported positive Phase 2 results for its lead drug KVD900, an oral therapy meant to stem the effects of swelling attacks caused by the rare ...
KalVista Pharmaceuticals Provides Regulatory Update for Phase 2 Clinical Trial of KVD824
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializatio...
KalVista Pharmaceuticals Appoints Nancy Stuart to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals, Inc. (KALV) Moves to Buy: Rationale Behind the Upgrade
KalVista Pharmaceuticals, Inc. (KALV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Misses Revenue Estimates
KalVista Pharmaceuticals, Inc. (KALV) delivered earnings and revenue surprises of 6.67% and -100.00%, respectively, for the quarter ended January 2021. Do the numbers hold clues to what lies ahead for t...
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals, Inc. (KALV) Expected to Beat Earnings Estimates: Should You Buy?
KalVista Pharmaceuticals, Inc. (KALV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KalVista Pharmaceuticals to Present at SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commer...
KalVista Pharmaceuticals Announces the Closing of its Upsized Public Offering of Common Stock and Full Exercise of th...
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the closing of its previously announced upsized public offering of 6,181,2...
KalVista Pharmaceuticals Raises $193.5M Via Equity To Fund KVD900 Development
KalVista Pharmaceuticals Inc (NASDAQ: KALV) prices its upsized underwritten public offering of 5.375 million at $36 per share, raising $193.5 million in gross proceeds. Earlier, the company offered 4.5 ...